Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future

Current Urology Reports

Volumn 9, Issue 2, 2008, Pages 113-121

  Murat, François Joseph L ^a   Gelet, Albert ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN;

BLADDER OBSTRUCTION; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EDEMA; EXTERNAL BEAM RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HORMONE SUBSTITUTION; HUMAN; MEDICAL TECHNOLOGIST; MORBIDITY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT INDICATION; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; ULTRASONIC THERAPY; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 41649118293     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0022-3     Document Type: Review

References (43)

1. Sim HG, Cheng CW: Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834-845.
2. Grönberg H: Prostate cancer epidemiology. Lancet 2003, 361:859-864.
3. Boccon-Gibod LM, Dumonceau O, Toublang M, et al.: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005, 48:895-899.
4. Adolfsson J, Tribukait B, Levitt S: The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumor ploidy and comorbidity. Eur Urol 2007, 52:1028-1035.
5. Wong YN, Mitra N, Hudes G, et al.: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693.
6. •• Ter Haar G, Coussios C: High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia 2007, 23:89-104. An excellent article about the physical principles of high-intensity focused ultrasound (HIFU).
7. Chapelon JY, Margonari J, Vernier F, et al.: In vivo effects of high-intensity ultrasound on prostate adenocarcinoma Dunning R3327. Cancer Res 1992, 52:6353-6357.
8. Rouviere O, Lyonnet D, Raudrant A, et al.: MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001, 40:265-274.
9. •• Rouviere O, Souchon R, Salomir R, et al.: Transrectal high-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. Eur J Radiol 2007, 63:317-327.
10. De Senneville BD, Mougenot C, Moonen CT: Real-time methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn Reson Med 2007, 57:319-330.
11. Illing RO, Leslie TA, Kennedy JE, et al.: Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 2006, 98:1187-1192.
12. Ficarra V, Antoniolli SZ, Novara G, et al.: Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 2006, 98:1193-1198.
13. Uchida T, Ohkusa H, Nagata Y, et al.: Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006, 97:56-61.
14. Blana A, Walter B, Rogenhofer S, Wieland WF: High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004, 63:297-300.
15. Chaussy C, Thuroff S: The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003, 4:248-252.
16. Lee HM, Hong JH, Choi HY: High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:439-443.
17. •• Poissonnier L, Chapelon JY, Rouviere O, et al.: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007, 51:381-387. An interesting article with a large population.
18. Vallancien G, Prapotnich D, Cathelineau X, et al.: Transrectal focused ultrasound combined with trans-urethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004, 171:2265-2267.
19. Thuroff S, Chaussy C, Vallancien G, et al.: High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003, 17:673-677.
20. Uchida T, Ohkusa H, Yamashita H, et al.: Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006, 13:228-233.
21. Uchida T, Illing RO, Cathcart PJ, Emberton M: To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006, 98:537-539.
22. Uchida T, Rowland O, Cathcart PJ, Emberton M: The effect of neoadjuvant androgen suppression on prostate-related outcomes after high-intensity focused ultrasound. BJU Int 2006, 98:770-772.
23. •• Blana A, Murat FJ, Walter B, et al.: First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2007, In press. The first multicenter study with long-term results.
24. Rebillard X, Davin JL, Soulie M, Comite de cancerologie de l'Association Française d'Urologie: Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 2003, 13:1428-1456.
25. Madersbacher S, Pedevilla M, Vingers L, et al.: Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995, 55:3346-3351.
26. Gelet A, Chapelon JY, Bouvier R, et al.: Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996, 29:174-183.
27. Chaussy C, Thuroff S: Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 2001, 15:437-440.
28. Ganzer R, Rogenhofer S, Walter B, et al.: PSA nadir is a significant predictor of treatment failure after high intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol, 2007, In press.
29. Gelet A, Chapelon JY, Bouvier R, et al.: Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001, 40:124-129.
30. Chaussy C, Thuroff S: High-intensity focused ultrasound in localized prostate cancer. J Endourol 2000, 14:293-299.
31. Thuroff S, Chaussy C: High-intensity focused ultrasound: complications and adverse effects. Mol Urol 2000, 4:183-187.
32. Chaussy C, Thuroff S, Rebillard X, Gelet A: Technology insight: high intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2005, 2:191-198.
33. Blana A, Rogenhofer S, Ganzer R, et al.: Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006, 24:585-590.
34. Pollack A, Hanlon AL, Horwitz EM, et al.: Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004, 171:1132-1136.
35. Shipley WU, Thames HD, Sandler HM, et al.: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999, 281:1598-1604.
36. Zelefsky MJ, Kuban DA, Levy LB, et al.: Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2005, 62:327-333.
37. Heinish M, Dirisamer A, Loidl W, et al.: Positron emission tomography/computed tomography with F-18-Fluorcholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006, 8:43-48.
38. Harisinghani MG, Barentsz J, Hahn PF, et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
39. Chaussy C, Thuroff S, Bergsdorf T: Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option [in German]. Urologe 2006, 45:1271-1275.
40. Murat FJ, Poissonnier L, Rouviere O, et al.: Salvage high intensity focused ultrasound (HIFU) treatment for recurrent prostate cancer after radiation therapy: High efficacy in patients with good initial prognosis [abstract 1777]. J Urol 2007, 177:591.
41. Ross AB, Diederich CJ, Nau WH, et al.: Curvilinear trans-urethral ultrasound applicator for selective prostate thermal therapy. Med Phys 2005, 32:1555-1565.
42. Piel JE, Watkins RD, Gross P, et al.: A transrectal focused ultrasound probe for MR-guided ablation of the prostate. Proceedings of the 13th scientific meeting of the international society for magnetic resonance in medicine. Miami: International Society for Magnetic Resonance in Medicine; 2005.
43. Paparel P, Curiel L, Chesnais S, et al.: Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005, 95:881-885.